Take a guy we’ll call James. He spent $3,200 on mycotoxin testing before anyone bothered to tell him the results might not mean what he thought they did.
He’d done a urine mycotoxin panel—one of the major commercial labs—and gotten results back showing elevated ochratoxin A and trichothecene levels. The lab report came with color-coded bars and alarming-looking “HIGH” markers next to several toxins. He immediately started a comprehensive detox protocol that cost him another $800 in supplements. Two months later, a second test showed similar results, and he panicked that the detox wasn’t working.
What James didn’t know—what nobody had told him—was that the reference ranges on those tests are largely uncalibrated to population norms. That “HIGH” marker meant his levels were above the lab’s internal reference range, which may or may not have been validated on a healthy population. Some studies have found measurable mycotoxins in urine samples of people with no mold exposure history and no symptoms. And without a pre-treatment baseline, he had no way to know if his levels had gone down, gone up, or stayed the same.
This guide breaks down every major mycotoxin testing option available, compares the leading commercial labs, explains the provocation protocol controversy, and gives a decision framework for figuring out which test—if any—is right for a given situation.
Why Mycotoxin Testing Is More Complicated Than It Looks
Let’s start with the fundamental challenge: mycotoxins are fat-soluble compounds that the body stores in fatty tissue and organs, releasing them slowly into circulation over time. The amount showing up in urine at any given moment is a function of multiple variables: how much exposure occurred, how long ago, how well Phase I and Phase II liver detox is functioning, whether any binders were taken that might have increased excretion, hydration status, and whether exercise happened recently (which mobilizes fat-stored toxins).
This is why raw urinary mycotoxin levels, without context, are hard to interpret. Two people with identical total mycotoxin body burdens might test very differently based on how well their detox systems are functioning. Someone with impaired liver detox might actually test lower despite having more stored toxins, because less is being excreted. Someone who exercised heavily before testing might test higher because mobilization is increased.
None of this means the tests are useless. It means they require clinical interpretation, not just a glance at color-coded bars. With proper context—clinical history, other diagnostic markers, temporal tracking, and knowledge of the specific lab’s methodology—urine mycotoxin testing can provide genuinely valuable information. Without that context, it’s an expensive piece of paper with limited clinical meaning.
“Urine mycotoxin testing can be a useful component of a comprehensive mold illness evaluation, but it should never be interpreted in isolation. The clinical picture—symptoms, biomarkers, environmental history—must always provide the interpretive framework.”
— Joseph Brewer, MD, Mold Illness specialist
The Testing Decision Tree: Your Framework for Choosing the Right Test
Before spending hundreds of dollars on testing, run through The Testing Decision Tree—a decision framework for determining what, if anything, to test and in what order:
- Step 1: Do you have symptoms? If yes—multiple symptoms across multiple systems consistent with mold illness—proceed to Step 2. If no significant symptoms, testing is unlikely to change management and is probably not warranted.
- Step 2: Have you done the free screening? Take the VCS test (survivingmold.com) and complete a symptom checklist. If both are negative, mold illness is less likely. If either is positive with clear multi-system symptoms, proceed.
- Step 3: Have you assessed your environment? Before expensive personal testing, assess the environment with an ERMI test. If your environment tests clean and you haven’t been in any suspicious buildings, personal mycotoxin testing is lower priority. If environment is contaminated, proceed to personal testing.
- Step 4: Do you need to confirm diagnosis or track treatment? If confirming diagnosis, start with the Shoemaker biomarker panel (C4a, TGF-beta-1, MSH, MMP-9, VEGF, VIP) through a physician—this is more clinically validated for CIRS diagnosis than urine mycotoxins. If tracking specific mycotoxin clearance on binder therapy, urine mycotoxin testing is more useful.
- Step 5: Which urine test? See the detailed lab comparison below. Choice depends on which mycotoxins are most clinically suspected based on mold species in the environment.
Urine Mycotoxin Testing: The Main Commercial Options
Three commercial labs dominate the urine mycotoxin testing space in the U.S.: Great Plains Laboratory (GPL), RealTime Labs, and Vibrant America (via their Mycotoxins panel). Each has a different methodology, different panel of tested mycotoxins, different pricing, and different strengths.
Great Plains Laboratory (GPL) — MycoTOX Profile:
The MycoTOX Profile tests for 11 mycotoxins using mass spectrometry (LC-MS/MS), including: ochratoxin A, aflatoxins (B1/B2/G1/G2), gliotoxin, trichothecenes (satratoxin, roridin A, verrucarin A), zearalenone, citrinin, and fumonisin B1. GPL uses UPLC-MS/MS methodology, which is one of the more analytically sensitive approaches available in commercial testing.
Strengths: Good trichothecene sensitivity (important for Stachybotrys exposure, the most dangerous household mold). Includes gliotoxin, which is a marker for Aspergillus fumigatus infection (not just exposure—fungal colonization in the sinuses or gut). Well-established lab with years of clinical data. Price: approximately $299-399.
Weaknesses: Reference ranges have been criticized for not being calibrated against a large general population sample. The “elevated” thresholds may reflect sensitivity of detection more than clinical significance. Requires careful clinical interpretation.
RealTime Labs — Mycotoxin Panel:
RealTime Labs tests for 16 mycotoxins using ELISA (enzyme-linked immunosorbent assay) methodology, including all three major trichothecene groups (macrocyclic, plus Group A and B), ochratoxin A, aflatoxins, gliotoxin, zearalenone, fumonisin, and several others. They also offer a comprehensive panel that includes additional biotoxins.
Strengths: The broadest panel of trichothecene testing available commercially—important because different Stachybotrys strains produce different trichothecene types, and getting the right ones matters. ELISA methodology is well-established for biological assays. Clinical laboratory with published validation data. Price: approximately $349-699 depending on panel.
Weaknesses: ELISA methodology can have cross-reactivity issues that produce false positives in some contexts. Some practitioners prefer mass spectrometry over ELISA for its specificity. RealTime’s reference ranges have also been questioned for similar reasons to GPL’s.
Vibrant America — Mycotoxins Panel:
Vibrant America uses a proprietary multiplex immunoassay platform (CLIA-certified laboratory) and tests for 31 mycotoxins—the most comprehensive commercially available panel. Includes all major trichothecenes, ochratoxin A and B, aflatoxins, fumonisins, zearalenone, deoxynivalenol (DON/vomitoxin), T-2 toxin, HT-2 toxin, and several others.
Strengths: Most comprehensive panel—broadest coverage of any commercial option. They have published calibration data against asymptomatic controls, which helps contextualize “elevated” findings. The platform also offers other tests that can be bundled for comprehensive functional medicine workups. Price: approximately $299-499.
Weaknesses: Immunoassay methodology may have lower specificity than mass spectrometry for individual mycotoxin identification. Being a newer entrant, fewer clinical practitioners have built up the same familiarity with interpreting their results compared to GPL or RealTime.
How to choose: For suspected Stachybotrys (black mold) exposure where trichothecenes are the primary concern—RealTime’s broad trichothecene panel has an advantage. For suspected Aspergillus or Penicillium where ochratoxin and aflatoxin are primary concerns—all three labs perform comparably. For the most comprehensive single test—Vibrant’s 31-mycotoxin panel. For integration with other functional lab work and clinical familiarity—GPL has the largest practitioner network.
Blood Testing for Mycotoxins: What It Can and Can’t Tell You
Blood mycotoxin testing is less commonly used than urine testing but has distinct applications. Most blood-based testing looks at mycotoxin metabolites and protein adducts—forms of mycotoxins that have bound to serum proteins.
Serum aflatoxin-albumin adducts: Aflatoxins bind to albumin (a serum protein) to form stable adducts that persist in the bloodstream for weeks. This makes serum aflatoxin-albumin testing a marker of cumulative exposure over the preceding 2-3 months—different from the “what’s currently being excreted” information urine tests provide. Used primarily in research and in occupational exposure monitoring (e.g., agricultural workers). Not widely available in standard commercial labs.
The Shoemaker CIRS biomarker panel (blood): While not testing for mycotoxins directly, the CIRS biomarker panel (C4a, TGF-beta-1, MSH, MMP-9, VEGF, VIP, ADH, etc.) provides blood-based evidence of the biological damage caused by mycotoxins. From a clinical diagnosis and treatment monitoring standpoint, this panel is more clinically validated for CIRS diagnosis than urine mycotoxin levels alone. Many practitioners prioritize this panel over urine mycotoxin testing for initial diagnosis.
Mold-specific IgG and IgE antibodies (blood): These test immune system sensitization to specific mold species—not mycotoxin exposure. They answer the question “has the immune system been exposed to this mold species and formed antibodies?” rather than “are these toxins present in the body?” Useful for confirming mold sensitization and for identifying specific species involved, but a different question than mycotoxin burden testing.
The Provocation Protocol: Does It Change Results?
Here’s where a significant controversy exists in the mycotoxin testing world. The “provocation” or “challenge” protocol involves taking agents that mobilize stored toxins—typically glutathione, DMSA, or saunas—before collecting urine, theoretically to increase the detectable amount of mycotoxins in the sample.
The argument for provocation: mycotoxins stored in fatty tissue may not show up in resting urine at detectable levels. Mobilizing them increases the amount excreted, making them detectable and providing a more accurate picture of total body burden. This is analogous to provoked heavy metal testing (though even that is controversial).
The argument against provocation: there are no validated reference ranges for provoked samples. All the reference data these labs have accumulated was presumably from unprovoked samples. Comparing a provoked result against unprovoked reference ranges is methodologically problematic—the numbers are inherently going to run higher against the same baseline. This can make healthy people look like they have dangerous mycotoxin burdens, leading to unnecessary treatment. Additionally, provocation can cause a genuine toxic mobilization reaction in already-ill patients.
The consensus among more cautious practitioners: do an unprovoked baseline test first. If results are borderline, a provoked test can help confirm whether there’s a genuine body burden versus analytical noise at the lower detection limit. Never interpret a provoked test against unprovoked reference ranges without acknowledging the methodological limitation.
Some labs explicitly offer “provoked” collection protocols; others test only unprovoked samples. Ask which reference ranges a given lab was built from.
Hair Analysis and Other Alternative Testing Methods
Hair mineral analysis: Tests hair for mineral content. Occasionally useful for heavy metal burden assessment (though even this is contested). Has no validated application for mycotoxin detection. The organizations claiming to diagnose mold illness primarily through hair analysis are on thin scientific ground.
Organic acids testing (OAT): The GPL Organic Acids Test includes markers for certain mold metabolites alongside markers for gut dysbiosis, mitochondrial function, neurotransmitter metabolism, and nutritional status. The arabinose marker on OAT can suggest intestinal yeast/fungal overgrowth. The test does not directly detect mold mycotoxins but provides useful functional context. Many mold-literate practitioners use the OAT as a companion to the MycoTOX panel.
Nasal and sinus cultures: Can identify fungal colonization in the sinuses—particularly relevant for Aspergillus and Candida overgrowth. Not a proxy for total mycotoxin burden but useful when sinus symptoms are predominant and fungal colonization (versus exposure) is suspected.
ERMI testing of environment (not the person): A DNA-based dust test for the building environment. Highly validated and clinically useful for identifying and quantifying mold species in the living or working environment. This tests the environment, not the body, but it’s often the most important first test—because finding mycotoxins in the body without an identified source is less actionable than finding mold in the environment.
Interpreting Your Results: What “Elevated” Actually Means
Across all the commercial urine mycotoxin labs, the most important interpretive challenge is the reference range. Here’s what matters.
How reference ranges are set: Ideally, reference ranges for any clinical test are established by measuring levels in a large sample of healthy, asymptomatic people and setting the cutoff at the 95th or 99th percentile. A result “above normal” means the level exceeds that of 95-99% of healthy individuals. Most mycotoxin labs have not published clearly validated reference ranges based on large population samples of asymptomatic controls. This is a genuine limitation of the field.
What a “HIGH” result means in practice: It means the level exceeded the lab’s internal reference threshold. Without knowing whether that threshold was validated in a healthy population, it’s hard to know whether “HIGH” means “clinically significant burden” or “above the 50th percentile of the general population.” This is not a reason to ignore elevated results—it’s a reason to interpret them clinically rather than in isolation.
Clinical context matters more than numbers: A person with 8+ CIRS symptoms, a positive VCS test, an elevated C4a, and above-reference-range urine ochratoxin is a completely different clinical picture than a person with no symptoms who happened to test high on ochratoxin after eating some grain-based foods (since dietary ochratoxin exposure from contaminated grains is common). The labs can’t make that distinction. A clinician can.
Trending matters more than absolute values: Test mycotoxin levels before starting binders and again after 4-8 weeks of binder therapy, and a downward trend is meaningful evidence that treatment is working—even if both values are “elevated” against the reference range. The direction and magnitude of change is more clinically useful than any single data point.
What Testing Cannot Tell You
This might be the most important section in this guide. Here’s what urine mycotoxin testing cannot do, regardless of which lab is used.
It cannot tell you definitively that mold illness is causing your symptoms. Even confirmed mycotoxin excretion doesn’t prove that those mycotoxins are responsible for a given symptom cluster—it means exposure has occurred and is being excreted. Causation requires clinical correlation.
It cannot tell you exactly where the exposure is coming from. Finding ochratoxin in urine confirms exposure to ochratoxin-producing molds (primarily Aspergillus and Penicillium), but not whether that’s from home, office, a car, a vacation rental, or food (grains and coffee are common dietary ochratoxin sources). Environmental testing is required to source the exposure.
It cannot tell you how severe the illness is. There is no established dose-response relationship between urinary mycotoxin levels and CIRS severity. Some severely ill patients test relatively low; some mildly symptomatic patients test very high. The Shoemaker biomarker panel is a better measure of CIRS severity than urine mycotoxin levels.
It cannot replace clinical judgment. No test result, taken alone, should drive a treatment decision. Testing informs clinical judgment—it doesn’t replace it.
“The goal of mycotoxin testing is not to find a number that tells you what to do. It’s to add a data point to a clinical picture that you’re building from multiple sources. Numbers without clinical context are just expensive noise.”
— Lisa Nagy, MD, environmental medicine specialist
The Practical Testing Protocol: How to Do This Right
Here’s how to sequence and execute mycotoxin testing to maximize clinical value and minimize wasted money.
- Environmental testing first. Run an ERMI test on primary living and working environments. This costs $200-400 and can confirm or rule out significant mold exposure before more is spent on personal testing.
- Free screening second. VCS test at survivingmold.com and symptom checklist. Takes 10 minutes and costs nothing.
- CIRS biomarker panel third (if symptomatic). Through a physician, run C4a, TGF-beta-1, MSH, MMP-9, VEGF, and VIP. This is the most clinically validated diagnostic panel for CIRS and is more useful for confirming diagnosis than urine mycotoxins.
- Urine mycotoxin testing fourth (if clinically indicated). Choose a lab based on suspected exposure species. Collect unprovoked morning first-void urine. Establish a baseline before starting any binder therapy.
- Retest at 6-8 weeks on binders. Same lab, same collection conditions. The change from baseline is the primary interpretive metric.
One more thing about James: once he found a practitioner who could properly interpret his results in context—using the full CIRS biomarker panel, his environmental history, and his VCS score—he discovered that his ochratoxin levels were indeed clinically significant and confirmed an Aspergillus exposure in a water-damaged office he’d been working in for two years. He remediated the exposure, started appropriate binder therapy, and saw measurable improvement in his biomarkers within six weeks. The testing was valuable. It just needed the right interpretive framework.
FAQ: Mycotoxin Testing
- Which mycotoxin test is most accurate? No single test is definitively “most accurate” because accuracy depends on what’s being tested for. Mass spectrometry methods (GPL MycoTOX) have high analytical specificity. RealTime Labs has the most comprehensive trichothecene panel. Vibrant covers the most mycotoxins in a single test. All three are CLIA-certified clinical laboratories using validated analytical methods. The choice depends on clinical context, not just analytical accuracy.
- How do I collect urine for mycotoxin testing? Collect the first void of the morning—the most concentrated sample. Use a clean container and follow the specific lab’s instructions for preservation (some require ice, some have preservatives in the collection container). Avoid excessive exercise in the 24 hours before collection (can artificially elevate levels through fat mobilization). Stay normally hydrated—neither dehydrated nor excessively hydrated (both affect concentration). Do not take glutathione or detox supplements the day before testing if doing an unprovoked baseline.
- Can I test myself for mold illness without a doctor? Urine mycotoxin tests can be ordered directly (without a physician order) through some labs or through direct-to-consumer health testing companies. However, interpreting the results without clinical context is limited in value and can lead to inappropriate treatment decisions. The CIRS biomarker panel requires physician ordering in most cases. The free VCS test and symptom checklist are excellent starting points that require no doctor.
- What if my test comes back normal but I still feel sick? A normal urine mycotoxin test doesn’t rule out mold illness. Several scenarios can produce normal results in sick people: the primary mycotoxins may not be ones covered by the panel chosen; detox function may be so impaired that very little is being excreted (low output despite high stored burden); or CIRS may have developed from a previous exposure whose toxins have largely cleared but whose inflammatory dysregulation persists. Assess with the CIRS biomarker panel and VCS test even if urine mycotoxins are normal.
- How long do mycotoxins stay in the body? This varies significantly by mycotoxin type. Water-soluble mycotoxins (like certain trichothecenes) are excreted relatively rapidly—within days to weeks of removing exposure. Fat-soluble mycotoxins (like aflatoxins and ochratoxin A) can be stored in fatty tissue for months to years, with slow ongoing release. This is why some people continue to excrete mycotoxins for extended periods after leaving a contaminated environment, and why binder therapy to interrupt the enterohepatic recirculation cycle is important for fat-soluble types.
- Should I test my children? Children in mold-contaminated environments are often more heavily exposed (higher respiration rate per body weight) and may develop CIRS. Testing children should be done under pediatric supervision. Many pediatricians are not familiar with CIRS testing; a functional medicine physician with pediatric experience or a CIRS-trained practitioner is a better choice. VCS testing is available and validated for children aged 8 and above.
- Is there any insurance coverage for mycotoxin testing? Generally no. Urine mycotoxin panels are not standard diagnostic tests recognized by most insurance providers. The Shoemaker CIRS biomarker panel components (C4a, TGF-beta-1, etc.) may be covered depending on the diagnostic codes used and the insurance plan. Check with the specific provider. Out-of-pocket costs typically range from $299 to $699 for a comprehensive urine mycotoxin panel.
Testing is one tool in the mold illness investigation toolkit—a useful one when used correctly and a misleading one when used without proper context. Build the clinical picture from multiple sources: symptoms, environment, CIRS biomarkers, and then mycotoxin levels.
Comparing Lab Reports: How to Read What You Get Back
GPL MycoTOX report format: GPL delivers results as a table with individual mycotoxin values in ppb (parts per billion) or creatinine-corrected equivalents, alongside colored reference bars. Red indicates above the lab’s reference range. The report includes brief interpretive notes about each mycotoxin’s sources and typical health associations. Importantly: the reference range values on GPL reports are sometimes labeled “creatinine-corrected, μg/g creatinine” and sometimes as raw concentration—check the units carefully, as they can look alarming if the measurement unit gets misread.
RealTime Labs report format: Organized by mycotoxin class (macrocyclic trichothecenes, Group A trichothecenes, aflatoxins, ochratoxin, etc.) with a flag system (H for high, L for low, * for very high) rather than a gradient bar. RealTime’s report includes their reference range cutoffs, which are set as absolute concentrations without creatinine correction in their standard reporting. Their trichothecene section includes multiple specific compounds that other labs don’t report individually, which can be helpful in identifying the specific Stachybotrys strain involved.
Vibrant America report format: The most visually modern format—uses a detailed graphic display showing the value against a reference distribution. Vibrant’s reports also include information about dietary sources for each mycotoxin alongside environmental sources, which is a useful reminder that high ochratoxin, for example, may reflect diet (contaminated grains, wine, coffee) rather than environmental mold exposure.
What to look for first: Trichothecenes (from Stachybotrys) are the most serious from a CIRS perspective and most indicative of water-damaged building exposure. Elevated macrocyclic trichothecenes almost certainly point to a heavily water-damaged building, not diet. Ochratoxin elevation alone is less specific—dietary sources are common. Aflatoxin elevation in someone without agricultural or industrial exposure strongly suggests environmental Aspergillus. The combination of multiple elevated mycotoxins from different mold genera is particularly significant—harder to explain by dietary exposure alone.
After the Test: What to Do With Your Results
Getting test results back is not the end of the process—it’s a specific data point that needs to be integrated into the clinical picture and acted upon. Here’s a structured approach to making decisions based on mycotoxin test results.
If results are normal and symptoms are significant: Don’t conclude mold illness is ruled out. Consider whether: the detection window for recent exposure has closed (tests within a few days of leaving a contaminated environment may show lower levels as excretion hasn’t peaked), detox function is impaired and limiting excretion (low output despite high burden), or the primary mycotoxins causing the illness are not in the panel chosen. Pursue the CIRS biomarker panel and VCS testing even with normal mycotoxin results if the clinical picture fits.
If results are elevated and symptoms are present: This combination is the most clinically actionable scenario. First priority: confirm or identify the environmental source. Elevated body burden with ongoing exposure means treatment will be undermined continuously. Complete environmental assessment first. Second: bring results to a CIRS-trained physician along with the full clinical picture for integrated assessment and protocol design. Third: begin the foundational aspects of treatment (dietary mycotoxin reduction, gentle binders, liver support) while waiting for the physician appointment.
If results are elevated without symptoms: This is the scenario most likely to lead to over-treatment. A “HIGH” flag on an ochratoxin result in a healthy, asymptomatic person eating commercial grain products may not require aggressive intervention. Discuss with a physician before starting pharmaceutical chelation or binder protocols based on asymptomatic elevated test results. Address the most likely dietary sources, retest in 3 months, and monitor for symptom development.
Tracking treatment response: Retest with the same lab, same collection conditions (same time of day, same hydration status, same pre-test activity level), at 6-8 week intervals on binder therapy. The target is a consistent downward trend across the mycotoxins that were elevated at baseline. Stabilizing or increasing levels despite treatment usually indicates ongoing exposure (most common), insufficient binder dose, or wrong binder for the mycotoxin type.
The Research Horizon: Where Mycotoxin Testing Is Heading
The field of mycotoxin testing is evolving rapidly, driven by increased awareness of CIRS, improvements in analytical chemistry, and growing research interest from both government and academic sources. Several developments are likely to improve testing accuracy and clinical utility in the next 5-10 years.
Population-calibrated reference ranges: The most significant gap in current testing is the lack of rigorously validated reference ranges built from large, well-characterized, asymptomatic population samples. Research groups are currently building these datasets, and future versions of commercial panels will have better statistical foundations for determining what levels are truly “abnormal” versus within the range of typical background exposure.
Metabolomics approaches: Rather than testing individual mycotoxins, metabolomics platforms can simultaneously screen for thousands of metabolites in a urine or blood sample, potentially identifying mycotoxin metabolites and biomarkers of mycotoxin exposure that current targeted panels miss. This approach may capture a broader picture of mycotoxin exposure, including metabolites of mycotoxins for which direct analytical methods don’t currently exist.
Exosome and biomarker research: Emerging research suggests that certain biomarkers in blood and urine—including specific inflammatory mediators, gene expression patterns in immune cells, and mitochondrial function markers—may be more sensitive and specific for CIRS severity than the mycotoxin levels themselves. These approaches may eventually allow diagnosis and treatment monitoring without requiring direct mycotoxin detection.
Integration with environmental testing: Future platforms may automatically cross-reference personal biomarker data with environmental testing data from the same household, using the combined dataset to identify probable causation and suggest targeted remediation. This kind of integrated environmental health platform doesn’t exist yet at scale, but the pieces (ERMI databases, mycotoxin biomonitoring data, CIRS biomarker databases) are being assembled.
For now, the best available testing is what’s been described in this guide—imperfect but clinically useful when properly contextualized. The key is working with a clinician who understands the limitations as well as the value, and building a clinical picture from multiple data sources rather than making decisions based on a single test result.
How to Prepare for Your Mycotoxin Test: Maximizing Result Quality
Pre-test preparation matters for the quality of results, and most labs provide minimal guidance on how to optimize the collection. Here’s what the evidence and clinical experience suggest for getting the most informative unprovoked baseline test.
Collection timing: First morning void is the optimal collection time for most mycotoxin labs. Overnight concentration means the urine contains the highest mycotoxin levels of the day, maximizing sensitivity for detecting low-level excretion. Some practitioners prefer a second morning void (urinate once upon waking, collect the second void 30-60 minutes later) to exclude the highly concentrated first void that may introduce variability—check the specific lab’s protocol recommendation.
Hydration before testing: Normal hydration is the goal. Being significantly dehydrated artificially elevates concentrations; being over-hydrated dilutes them. Don’t drink excessive water the day before testing to “flush out” toxins—this simply dilutes the sample and may cause false-low results. Maintain normal daily fluid intake in the 24 hours before collection.
Activity level: Avoid vigorous exercise in the 24-48 hours before testing. Exercise mobilizes fat-stored compounds into circulation and can temporarily elevate urinary excretion of fat-soluble mycotoxins, potentially producing a higher reading than reflects true baseline. A moderately active but not intensely exercising day is ideal.
Avoid binders before baseline testing: This is critical. When testing to establish a baseline before starting binder therapy, do not take activated charcoal, cholestyramine, chlorella, or any other binder for at least 48-72 hours before the test. Binders increase mycotoxin excretion and would elevate the baseline, potentially inflating it beyond the true resting level and making it harder to track treatment progress accurately.
Avoid glutathione and detox supplements before baseline: Similarly, glutathione (IV or oral), NAC, and other detox supports that increase mobilization and excretion should be paused for 48 hours before a baseline test. These are appropriate during treatment, but taking them immediately before a baseline test creates a provoked sample that should be interpreted against provoked reference ranges—not the standard unprovoked ranges the lab uses.
Dietary consistency: Eat a normal diet in the days before testing. Dramatic dietary changes (eliminating grains, coffee, or other common dietary mycotoxin sources) in the days before the test can produce lower ochratoxin or aflatoxin levels that reflect the dietary change rather than actual environmental exposure pattern. Consistency allows the test to reflect real-world exposure, which is what’s clinically relevant.
Sample handling: Follow the lab’s specific instructions for sample preservation and shipping. Most labs require immediate refrigeration or freezing of the sample after collection, and provide a pre-paid expedited shipping label. Samples left at room temperature for extended periods can degrade, producing falsely low results. If same-day shipping isn’t possible, freeze the sample per lab instructions and ship at the earliest opportunity.
The Cost-Value Analysis: What Each Test Option Actually Buys You
Given the significant out-of-pocket cost of mycotoxin testing, a systematic cost-value analysis helps decide where to invest a testing budget for maximum clinical return.
ERMI environmental test ($200-400): The highest clinical value per dollar for anyone who suspects environmental mold exposure. It answers the question “is there significant mold in this environment?” before more is spent on personal testing. If the ERMI is clean and the person has been predominantly in that environment, personal mycotoxin testing is much lower priority. If the ERMI shows significant contamination, personal testing becomes much more relevant. Do this first.
VCS test (free): Takes five minutes. Do it before spending any money on personal testing. A passing VCS test in someone with significant symptoms doesn’t rule out CIRS, but it does reduce its probability somewhat. A failing VCS test in someone with multi-system symptoms is a significant data point that supports pursuing further investigation.
Shoemaker CIRS biomarker panel ($300-600 out-of-pocket): More clinically validated for CIRS diagnosis than urine mycotoxin testing, and more useful for monitoring treatment response in terms of the biological processes that matter most. Choosing between this panel and a urine mycotoxin panel with a limited budget, the CIRS biomarker panel typically provides more actionable clinical information. However, some insurance will cover components of this panel where urine mycotoxins are entirely out-of-pocket.
Urine mycotoxin panel ($299-699): Best value when: a confirmed contaminated environment exists and personal exposure needs documenting; specific mycotoxin types need identifying to guide binder selection; treatment progress is being monitored and declining levels need tracking; or CIRS biomarkers are ambiguous and additional data is needed to confirm the mold connection. Lower value as a standalone screening test in the absence of environmental documentation and clinical context.
Combining tests strategically: The most clinically powerful combination is: ERMI environmental test (confirm exposure) + VCS test (confirm neurological impact) + abbreviated CIRS biomarker panel (C4a and TGF-beta-1 minimum, MSH if available) + GPL MycoTOX urine test (confirm specific mycotoxins). This combination provides overlapping lines of evidence that are far more compelling than any single test alone, and creates a clear baseline for tracking treatment response. Total cost: approximately $700-1200 out-of-pocket. That’s significant, but it’s also the cost of one month of incorrect treatment for the wrong diagnosis—which many CIRS patients have spent years accumulating.
For the full diagnostic and treatment protocol, see our complete Mold Illness Recovery Protocol.
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map